register

News & Trends - Pharmaceuticals

MSD’s GARDASIL 9 approved for head and neck cancers

Health Industry Hub | June 17, 2020 |

Pharma News: Merck, known as MSD outside the United States and Canada, announced the U.S. Food and Drug Administration (FDA) approval of an expanded indication for GARDASIL 9 for the prevention of oropharyngeal and other head and neck cancers caused by HPV genotypes 16, 18, 31, 33, 45, 52, and 58.

HPV is estimated to cause more than 90 percent of anal and cervical cancers, around 70 percent of vaginal cancers, and 60 percent of penile cancers. Previously, oropharyngeal cancers were largely thought to be caused by tobacco and alcohol use, but based on recent studies, experts believe as much as 70 percent of head and neck cancers may be due to HPV infections.

“At Merck, working to help prevent certain HPV-related cancers has been a priority for more than two decades,” said Dr. Alain Luxembourg, director, clinical research, Merck Research Laboratories. “The approval for the prevention of HPV-related oropharyngeal and other head and neck cancers represents an important step in Merck’s mission to help reduce the number of men and women affected by certain HPV-related cancers.”

Register-and-join-Health-Industry-Hub-Pharma-MedTech-Biotech

In February, Merck launched a 6,000-patient study to evaluate the efficacy and safety of its vaccine to prevent oral HPV infection in men between 20 and 45 years of age. HPV-related oropharyngeal cancers, which occur at the back of the throat and often involves the base of the tongue and tonsils, affect men five times more than women. 

Both men and women can be at risk for HPV-attributable oropharyngeal cancer; however, this cancer affects men five times more than women. For most people, HPV clears on its own. But, for those who don’t clear the virus, it can cause certain cancers.

In Australia, GARDASIL 9 is indicated in females aged 9 to 45 years for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by Human Papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52 and 58. In males 9 to 26 years of age it is indicated for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infection caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58.


News & Trends - Pharmaceuticals

Manoj Saxena - Bayer

Breaking the mold: Bayer GM on the future of pharma workplaces – Reimagining Healthcare Senior Leadership Series

Health Industry Hub | July 18, 2024 |

In the latest episode of the Reimagining Healthcare senior leadership series, Manoj Saxena, General Manager Pharmaceuticals ANZ at Bayer voiced […]

More


News & Trends - Pharmaceuticals

Matt Zeller, Country President of Novartis ANZ

Novartis Country President talks essentials in shaping the future of health policy: Reimagining Healthcare senior leadership series

Health Industry Hub | July 18, 2024 |

In this episode of the Reimagining Healthcare senior leadership series, Matt Zeller, Country President of Novartis ANZ, explores how health […]

More


Medical

First guidelines to stamp out rising scientific integrity issues in medical journals

First guidelines to stamp out rising scientific integrity issues in medical journals

Health Industry Hub | July 18, 2024 |

The number of retractions issued for scientific research articles in 2023 exceeded 10,000 – smashing annual records. To date, publishers […]

More


News & Trends - Pharmaceuticals

Gilead secures MSAC nod for CAR-T therapy

Gilead secures MSAC nod for CAR-T therapy

Health Industry Hub | July 18, 2024 |

Pharma News: Gilead Sciences welcomes the Medical Services Advisory Committee (MSAC) recommendation for public funding of Yescarta (axicabtagene ciloleucel) as […]

More


This content is copyright protected. Please subscribe to gain access.